Literature DB >> 8919596

Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers.

A S Chuck1, B O Palsson.   

Abstract

Flow-through transduction methods have been developed to overcome physical limitations imposed by Brownian motion on retroviral delivery. This method uses net fluid flow of retroviral supernatants through a porous membrane on which the target cells are placed. It is shown that in comparison to static transduction methods, flow-through transductions have the following advantages: (i) flow-through transductions lead to transduction rates that exceed those obtained by static transduction; (ii) flow-through transductions lead to high transduction rates even at low viral concentrations, eliminating many of the concerns associated with the production of high-titer virus supernatants; (iii) flow-through transductions are insensitive to viral titers, eliminating the need to produce consistently retroviral supernatants at given virus concentrations; (iv) flow-through transductions can be carried out without the use of polycations, such as polybrene; and (v) the volume of viral supernatants needed for gene transfer can be sharply reduced. Taken together, these advantages of flow-through transductions are likely to lead to their widespread use for gene transfer work, both in research and clinical settings.

Mesh:

Year:  1996        PMID: 8919596     DOI: 10.1089/hum.1996.7.6-743

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  23 in total

1.  Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis.

Authors:  Young Jik Kwon; Gene Hung; W French Anderson; Ching-An Peng; Hong Yu
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours.

Authors:  S T Andreadis; D Brott; A O Fuller; B O Palsson
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Justification of continuous packed-bed reactor for retroviral vector production from amphotropic PsiCRIP murine producer cell.

Authors:  S H Kang; B G Kim; G M Lee
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

5.  Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo.

Authors:  C D Porter; K V Lukacs; G Box; Y Takeuchi; M K Collins
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Stochastic model-assisted development of efficient low-dose viral transduction in microfluidics.

Authors:  Camilla Luni; Federica Michielin; Luisa Barzon; Vincenza Calabrò; Nicola Elvassore
Journal:  Biophys J       Date:  2013-02-19       Impact factor: 4.033

7.  Primary attachment of murine leukaemia virus vector mediated by particle-associated heparan sulfate proteoglycan.

Authors:  Nina Kureishy; Daisy Faruque; Colin D Porter
Journal:  Biochem J       Date:  2006-12-15       Impact factor: 3.857

8.  Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor.

Authors:  C E Dunbar; N E Seidel; S Doren; S Sellers; A P Cline; M E Metzger; B A Agricola; R E Donahue; D M Bodine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

9.  Pseudotype formation of Moloney murine leukemia virus with Sendai virus glycoprotein F.

Authors:  M Spiegel; M Bitzer; A Schenk; H Rossmann; W J Neubert; U Seidler; M Gregor; U Lauer
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

10.  Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.

Authors:  C J Gordon; M A Muesing; A E Proudfoot; C A Power; J P Moore; A Trkola
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.